Dr Shaun Ho is an experienced radiation oncologist and specialises in advanced radiotherapy techniques including proton beam therapy (PBT), stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), as well as intensity modulated/volumetric modulated arc radiotherapy (IMRT/VMAT). He has a special interest in the treatment of colorectal cancer, oesophagus, liver and pancreatic cancers, head and neck cancers, breast cancer, lung cancer, prostate cancer, sarcomas, lymphomas, and brain tumours.

Dr Ho completed his radiation oncology residency at the National Cancer Centre Singapore (NCCS) and subsequently a fellowship in Clinical Oncology at University College London Hospital (UCLH) in the UK. During his fellowship, he treated patients at UCH Macmillan Cancer Centre, the National Hospital for Neurology and Neurosurgery (NHNN), and was part of the London Sarcoma Service, one of the largest sarcoma services in Europe. His subspecialty training was in gastrointestinal oncology, neuro-oncology, sarcomas and lymphomas. He also underwent further training in proton beam therapy (PBT) at Kobe Proton Therapy Center in Japan, and at Taipei Medical University Hospital in Taiwan.

Dr Ho is a Fellow of the Academy of Medicine Singapore and the UK Royal College of Radiologists (Clinical Oncology) and a Member of the Royal College of Surgeons of Edinburgh. Additionally, he holds a Graduate Diploma in Palliative Medicine. To advance the radiation oncology specialty in Singapore, Dr Ho served on the Executive Committees of the Chapter of Radiation Oncologists, College of Radiologists Singapore, and the Singapore Radiological Society. He is also a member of the International Society for Radiosurgery.

Dr Ho was formerly the Clinical Director of Radiation Oncology Services at Raffles Hospital where he established and operationalised their first radiotherapy services, which included techniques such as SBRT for lung and bone tumours, SRS for brain metastases, deep inspiratory breath-hold (DIBH) radiotherapy for breast cancer, and VMAT for cancers in the head and neck, lung, and prostate.